Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Colorcon
Mallinckrodt
Merck
Johnson and Johnson

Last Updated: December 8, 2021

DrugPatentWatch Database Preview

Patent: 10,351,627

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 10,351,627
Title:ICOS binding proteins
Abstract: The present invention relates to an ICOS binding protein or antigen binding portion thereof that is an agonist to human ICOS and does not induce complement, ADCC, or CDC when placed in contact with a T cell in vivo and methods of treating cancer, infectious disease and/or sepsis with said ICOS binding protein or antigen binding portion thereof. Further the ICOS binding proteins or antigen binding portions thereof of the present invention are capable of activating a T cell when placed in contact with said T cell; stimulating T cell proliferation when placed in contact with said T cell and/or inducing cytokine production when placed in contact with said T cell. The present invention relates to ICOS binding proteins or antigen binding portions thereof comprising one or more of: SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; and/or SEQ ID NO:6.
Inventor(s): Liu; Yao-Bin (Collegeville, PA), Mayes; Patrick (Collegeville, PA), Parmar; Radha Shah (Stevenage, GB)
Assignee: GlaxoSmithKline Intellectual Property Development Limited (Brentford, Middlesex, GB)
Application Number:15/246,662
Patent Claims:see list of patent claims

Details for Patent 10,351,627

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Bristol-myers Squibb Company YERVOY ipilimumab Injection 125377 2011-03-25 ⤷  Free Forever Trial 2039-07-27
Merck Sharp & Dohme Corp. KEYTRUDA pembrolizumab For Injection 125514 2014-09-04 ⤷  Free Forever Trial 2039-07-27
Merck Sharp & Dohme Corp. KEYTRUDA pembrolizumab Injection 125514 2015-01-15 ⤷  Free Forever Trial 2039-07-27
Bristol-myers Squibb Company OPDIVO nivolumab Injection 125554 2014-12-22 ⤷  Free Forever Trial 2039-07-27
Bristol-myers Squibb Company OPDIVO nivolumab Injection 125554 2017-10-04 ⤷  Free Forever Trial 2039-07-27
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
Colorcon
Express Scripts
Merck
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.